medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2021-4-230-239medsovet-6113Research ArticleПРАКТИКАPRACTICEПерименопаузальный период и нарушения настроенияPerimenopausal period and mood disordershttps://orcid.org/0000-0002-7465-0677ПизоваН. В.PizovaN. V.

Пизова Наталия Вячеславовна, доктор медицинских наук, профессор, профессор кафедры нервных болезней с медицинской генетикой и нейрохирургией

150000, Ярославль, ул. Революционная, д. 5

Nataliia V. Pizova, Dr. Sci. (Med.), Professor, Professor of the Department of Nervous Diseases with Medical Genetics and Neurosurgery

5, Revolutsionnaya St., Yaroslavl, 150000

pizova@yandex.ruhttps://orcid.org/0000-0002-3009-3020ПизовН. А.PizovN. A.

Пизов Николай Александрович, аспирант кафедры нервных болезней с медицинской генетикой и нейрохирургией

150000, Ярославль, ул. Революционная, д. 5

Nikolai A. Pizov, Postgraduate Student of the Department of Nervous Diseases with Medical Genetics and Neurosurgery

5, Revolutsionnaya St., Yaroslavl, 150000

pizov.n.a@gmail.comhttps://orcid.org/0000-0002-0522-675XПизовА. В.PizovA. V.

Пизов Александр Витальевич, кандидат биологических наук, доцент кафедры медицины

150000, Ярославль, ул. Республиканская, д. 108/1

Aleksandr V. Pizov, Cand. Sci. (Biol.), Associate Professor of the Department of Medicine

108/1, Republikanskaya St., Yaroslavl, 150000

avpizov@yandex.ruЯрославский государственный медицинский университетРоссияYaroslavl State Medical UniversityRussian FederationЯрославский государственный педагогический университет имени К.Д. УшинскогоРоссияYaroslavl State Pedagogical University named after K.D. UshinskyRussian Federation20212004202104230239Copyright © Пизова Н.В., Пизов Н.А., Пизов А.В., 20212021Пизова Н.В., Пизов Н.А., Пизов А.В.Pizova N.V., Pizov N.A., Pizov A.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/6113

Статья посвящена возможностям коррекции психоневрологических нарушений в  перименопаузе  – состоянии, связанном с прекращением у женщины менструации и снижением уровня стероидных гормонов яичников (эстрогена и прогестерона) из-за потери фолликулярной массы яичников. Известно, что биологические и эндокринные изменения в этот период часто сопровождаются вегетативными симптомами. В перименопаузе женщины могут испытывать такие симптомы, как приливы и ночная потливость, бессонница, сухость влагалища, расстройства настроения и т. д. Хотя большинство симптомов не опасны для жизни, они могут оказывать негативное влияние на качество жизни, физическое и психическое здоровье женщин в перименопаузе. В период менопаузы женщины подвержены более высокому риску развития депрессии, стресса, беспокойства и эмоционального расстройства. Кроме того, во время перименопаузы у женщин наблюдаются не только депрессивные симптомы, но и когнитивные нарушения, которые могут быть связаны с изменениями гормонального фона. Лекарственные препараты, которые применяются в терапии нарушений настроения, воздействуют на различные нейротрансмиттеры, в частности на серотонин, норадреналин, гамма-аминомасляную кислоту (ГАМК). Одним из препаратов из группы производных бензодиазепина является тофизопам, впервые разработанный в Венгрии и продаваемый в ряде европейских стран под названием Грандаксин. Препарат показан для лечения невротических и соматических расстройств, связанных с  напряжением, тревогой, вегетативными расстройствами, отсутствием энергии и  мотивации, апатии, утомляемости, подавленного настроения и алкогольного абстинентного синдрома, в т. ч. в период перименопаузы. Тофизопам обладает хорошей анксиолитической активностью, не оказывая заметных седативных, противосудорожных, амнестических или миорелаксантных эффектов.

The article is devoted to the possibilities of correction of neuropsychiatric disorders in perimenopause, a condition associated with the cessation of menstruation in a woman and a decrease in the level of ovarian steroid hormones (estrogen and progesterone) due to the loss of the ovarian follicular mass. It is known that biological and endocrine changes during this period are often accompanied by autonomic symptoms. In perimenopause, women may experience symptoms such as hot flashes and night sweats, insomnia, vaginal dryness, mood disorders, etc. Although most symptoms are not life-threatening, they can have a negative impact on the quality of life, physical and mental health of perimenopausal women. During menopause, women are at higher risk of developing depression, stress, anxiety and emotional disorders. In addition, during perimenopause, women experience not only depressive symptoms but also cognitive impairment, which may be related to changes in hormonal background. Drugs that are used in the treatment of mood disorders affect different neurotransmitters, in particular serotonin, norepinephrine and gamma-aminobutyric acid (GABA). One of the benzodiazepine derivatives is Tofisopam, first developed in Hungary and marketed in a number of European countries under the name Grandaxin. It is indicated for the treatment of neurotic and somatic disorders associated with tension, anxiety, autonomic disorders, lack of energy and motivation, apathy, fatigue, depressed mood and alcohol withdrawal syndrome, including during perimenopause. Tofisopam has good anxiolytic activity with no observable sedative, anticonvulsant, amnestic or muscle relaxant effects.

перименопаузапсихоневрологические нарушениянарушения настроенидепрессиястрессгормональный фонтофизопамperimenopauseneuropsychiatric disordersmood disordersdepressionstresshormonal backgroundtofisopamReferencesXiao C., Mou C., Zhou X. Effect of Mindfulness Meditation Training on Anxiety, Depression and Sleep Quality in Perimenopausal Women. Nan Fang Yi Ke Da Xue Xue Bao. 2019;39(8):998–1002. doi: 10.12122/j.issn.1673-4254.2019.08.19.Xiao C., Mou C., Zhou X. Effect of Mindfulness Meditation Training on Anxiety, Depression and Sleep Quality in Perimenopausal Women. Nan Fang Yi Ke Da Xue Xue Bao. 2019;39(8):998–1002. doi: 10.12122/j.issn.1673-4254.2019.08.19.Lobo R.A. Menopause and Sexuality: Is There a Role for Androgen Therapy? Menopause Management for the Millennium. Available at: https://www.medscape.org/viewarticle/413064_25.Lobo R.A. Menopause and Sexuality: Is There a Role for Androgen Therapy? Menopause Management for the Millennium. Available at: https://www.medscape.org/viewarticle/413064_25.Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging. J Clin Endocrinol Metab. 2012;97(4):1159–1168. doi: 10.1210/jc.2011-3362.Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging. J Clin Endocrinol Metab. 2012;97(4):1159–1168. doi: 10.1210/jc.2011-3362.Soules M.R., Sherman S., Parrott E., Rebar R., Santoro N., Utian W., Woods N. Executive Summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001;76(5):874–878. doi: 10.1016/s0015-0282(01)02909-0.Soules M.R., Sherman S., Parrott E., Rebar R., Santoro N., Utian W., Woods N. Executive Summary: Stages of Reproductive Aging Workshop (STRAW). Fertil Steril. 2001;76(5):874–878. doi: 10.1016/s0015-0282(01)02909-0.Liu M., Wang Y., Li X., Liu P., Yao C., Ding Y. et al. A Health Survey of Beijing Middle-Aged Registered Nurses during Menopause. Maturitas. 2013;74(1):84–88. doi: 10.1016/j.maturitas.2012.10.006.Liu M., Wang Y., Li X., Liu P., Yao C., Ding Y. et al. A Health Survey of Beijing Middle-Aged Registered Nurses during Menopause. Maturitas. 2013;74(1):84–88. doi: 10.1016/j.maturitas.2012.10.006.Jaspers L., Daan N.M., van Dijk G.M., Gazibara T., Muka T., Wen K.X. et al. Health in Middle-Aged and Elderly Women: A Conceptual Framework for Healthy Menopause. Maturitas. 2015;81(1):93–98. doi: 10.1016/j.maturitas.2015.02.010.Jaspers L., Daan N.M., van Dijk G.M., Gazibara T., Muka T., Wen K.X. et al. Health in Middle-Aged and Elderly Women: A Conceptual Framework for Healthy Menopause. Maturitas. 2015;81(1):93–98. doi: 10.1016/j.maturitas.2015.02.010.Hulka B.S., Meirik O. Research on the Menopause. Maturitas. 1996;23(2):109–112. doi: 10.1016/0378-5122(95)00967-1.Hulka B.S., Meirik O. Research on the Menopause. Maturitas. 1996;23(2): 109–112. doi: 10.1016/0378-5122(95)00967-1.Yim G., Ahn Y., Chang Y., Ryu S., Lim J.Y., Kang D. et al. Prevalence and Severity of Menopause Symptoms and Associated Factors Across Menopause Status in Korean Women. Menopause. 2015;22(10):1108–1116. doi: 10.1097/GME.0000000000000438.Yim G., Ahn Y., Chang Y., Ryu S., Lim J.Y., Kang D. et al. Prevalence and Severity of Menopause Symptoms and Associated Factors Across Menopause Status in Korean Women. Menopause. 2015;22(10):1108–1116. doi: 10.1097/GME.0000000000000438.Moilanen J., Aalto A.M., Hemminki E., Aro A.R., Raitanen J., Luoto R. Prevalence of Menopause Symptoms and Their Association with Lifestyle among Finnish Middle-Aged Women. Maturitas. 2010;67(4):368–374. doi: 10.1016/j.maturitas.2010.08.007.Moilanen J., Aalto A.M., Hemminki E., Aro A.R., Raitanen J., Luoto R. Prevalence of Menopause Symptoms and Their Association with Lifestyle among Finnish Middle-Aged Women. Maturitas. 2010;67(4):368–374. doi: 10.1016/j.maturitas.2010.08.007.El Shafie K., Al Farsi Y., Al Zadjali N., Al Adawi S., Al Busaidi Z., Al Shafaee M. Menopausal Symptoms among Healthy, Middle-Aged Omani Women as Assessed with the Menopause Rating Scale. Menopause. 2011;18(10):1113–1119. doi: 10.1097/gme.0b013e31821b82ee.El Shafie K., Al Farsi Y., Al Zadjali N., Al Adawi S., Al Busaidi Z., Al Shafaee M. Menopausal Symptoms among Healthy, Middle-Aged Omani Women as Assessed with the Menopause Rating Scale. Menopause. 2011;18(10):1113–1119. doi: 10.1097/gme.0b013e31821b82ee.Pérez J.A., Garcia F.C., Palacios S., Pérez M. Epidemiology of Risk Factors and Symptoms Associated with Menopause in Spanish Women. Maturitas. 2009;62(1):30–36. doi: 10.1016/j.maturitas.2008.10.003.Pérez J.A., Garcia F.C., Palacios S., Pérez M. Epidemiology of Risk Factors and Symptoms Associated with Menopause in Spanish Women. Maturitas. 2009;62(1):30–36. doi: 10.1016/j.maturitas.2008.10.003.Greenblum C.A., Rowe M.A., Neff D.F., Greenblum J.S. Midlife Women: Symptoms Associated with Menopausal Transition and Early Postmenopause and Quality of Life. Menopause. 2013;20(1):22–27. doi: 10.1097/gme.0b013e31825a2a91.Greenblum C.A., Rowe M.A., Neff D.F., Greenblum J.S. Midlife Women: Symptoms Associated with Menopausal Transition and Early Postmenopause and Quality of Life. Menopause. 2013;20(1):22–27. doi: 10.1097/gme.0b013e31825a2a91.Kim Y., Austin S.B., Subramanian S.V., Kawachi I. Body Weight Perception, Disordered Weight Control Behaviors, and Depressive Symptoms among Korean Adults: The Korea National Health and Nutrition Examination Survey 2014. PLoS One. 2018;13(6):e0198841. doi: 10.1371/journal.pone.0198841.Kim Y., Austin S.B., Subramanian S.V., Kawachi I. Body Weight Perception, Disordered Weight Control Behaviors, and Depressive Symptoms among Korean Adults: The Korea National Health and Nutrition Examination Survey 2014. PLoS One. 2018;13(6):e0198841. doi: 10.1371/journal.pone.0198841.Al-Safi Z.A., Santoro N. Menopausal Hormone Therapy and Menopausal Symptoms. Fertil Steril. 2014;101(4):905–915. doi: 10.1016/j.fertnstert.2014.02.032.Al-Safi Z.A., Santoro N. Menopausal Hormone Therapy and Menopausal Symptoms. Fertil Steril. 2014;101(4):905–915. doi: 10.1016/j.fertnstert.2014.02.032.Monteleone P., Mascagni G., Giannini A., Genazzani A.R., Simoncini T. Symptoms of Menopause – Global Prevalence, Physiology and Implications. Nat Rev Endocrinol. 2018;14(4):199–215. doi: 10.1038/nrendo.2017.180.Monteleone P., Mascagni G., Giannini A., Genazzani A.R., Simoncini T. Symptoms of Menopause – Global Prevalence, Physiology and Implications. Nat Rev Endocrinol. 2018;14(4):199–215. doi: 10.1038/nrendo.2017.180.Guthrie J.R., Dennerstein L., Taffe J.R., Donnelly V. Health Care-Seeking for Menopausal Problems. Climacteric. 2003;6(2):112–117. doi: 10.1080/cmt.6.2.112.117.Guthrie J.R., Dennerstein L., Taffe J.R., Donnelly V. Health Care-Seeking for Menopausal Problems. Climacteric. 2003;6(2):112–117. doi: 10.1080/cmt.6.2.112.117.Llaneza P., García-Portilla M.P., Llaneza-Suárez D., Armott B., Pérez-López F.R. Depressive Disorders and the Menopause Transition. Maturitas. 2012;71(2):120–130. doi: 10.1016/j.maturitas.2011.11.017.Llaneza P., García-Portilla M.P., Llaneza-Suárez D., Armott B., Pérez-López F.R. Depressive Disorders and the Menopause Transition. Maturitas. 2012;71(2):120–130. doi: 10.1016/j.maturitas.2011.11.017.Cohen L.S., Soares C.N., Vitonis A.F., Otto M.W., Harlow B.L. Risk for New Onset of Depression during the Menopausal Transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2006;63(4):385–390. doi: 10.1001/archpsyc.63.4.385.Cohen L.S., Soares C.N., Vitonis A.F., Otto M.W., Harlow B.L. Risk for New Onset of Depression during the Menopausal Transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2006;63(4):385–390. doi: 10.1001/archpsyc.63.4.385.Melby M.K., Lock M., Kaufert P. Culture and Symptom Reporting at Menopause. Hum Reprod Update. 2005;11(5):495–512. doi: 10.1093/humupd/dmi018.Melby M.K., Lock M., Kaufert P. Culture and Symptom Reporting at Menopause. Hum Reprod Update. 2005;11(5):495–512. doi: 10.1093/humupd/dmi018.ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202–216. doi: 10.1097/01.AOG.0000441353.20693.78.ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123(1):202–216. doi: 10.1097/01.AOG.0000441353.20693.78.Politi M.C., Schleinitz M.D., Col N.F. Revisiting the Duration of Vasomotor Symptoms of Menopause: A Meta-Analysis. J Gen Intern Med. 2008;23(9):1507–1513. doi: 10.1007/s11606-008-0655-4.Politi M.C., Schleinitz M.D., Col N.F. Revisiting the Duration of Vasomotor Symptoms of Menopause: A Meta-Analysis. J Gen Intern Med. 2008;23(9):1507–1513. doi: 10.1007/s11606-008-0655-4.Zheng H., Harlow S.D., Kravitz H.M., Bromberger J., Buysse D.J., Matthews K.A. et al. Actigraphy-Defined Measures of Sleep and Movement across the Menstrual Cycle in Midlife Menstruating Women: Study of Women’s Health Across the Nation Sleep Study. Menopause. 2015;22(1):66–74. doi: 10.1097/GME.0000000000000249.Zheng H., Harlow S.D., Kravitz H.M., Bromberger J., Buysse D.J., Matthews K.A. et al. Actigraphy-Defined Measures of Sleep and Movement across the Menstrual Cycle in Midlife Menstruating Women: Study of Women’s Health Across the Nation Sleep Study. Menopause. 2015;22(1):66–74. doi: 10.1097/GME.0000000000000249.Kravitz H.M., Zhao X., Bromberger J.T., Gold E.B., Hall M.H., Matthews K.A., Sowers M.R. Sleep Disturbance during the Menopausal Transition in a Multi-Ethnic Community Sample of Women. Sleep. 2008;31(7): 979–990. doi: 10.5665/sleep/31.7.979.Kravitz H.M., Zhao X., Bromberger J.T., Gold E.B., Hall M.H., Matthews K.A., Sowers M.R. Sleep Disturbance during the Menopausal Transition in a Multi-Ethnic Community Sample of Women. Sleep. 2008;31(7): 979–990. doi: 10.5665/sleep/31.7.979.Guérin E., Goldfield G., Prud’homme D. Trajectories of Mood and Stress and Relationships with Protective Factors during the Transition to Menopause: Results using Latent Class Growth Modeling in a Canadian Cohort. Arch Womens Ment Health. 2017;20(6):733–745. doi: 10.1007/s00737-017-0755-4.Guérin E., Goldfield G., Prud’homme D. Trajectories of Mood and Stress and Relationships with Protective Factors during the Transition to Menopause: Results using Latent Class Growth Modeling in a Canadian Cohort. Arch Womens Ment Health. 2017;20(6):733–745. doi: 10.1007/s00737-017-0755-4.Gold E.B., Sternfeld B., Kelsey J.L., Brown C., Mouton C., Reame N. et al. Relation of Demographic and Lifestyle Factors to Symptoms in a MultiRacial/Ethnic Population of Women 40–55 Years of Age. Am J Epidemiol. 2000;152(5):463–473. doi: 10.1093/aje/152.5.463.Gold E.B., Sternfeld B., Kelsey J.L., Brown C., Mouton C., Reame N. et al. Relation of Demographic and Lifestyle Factors to Symptoms in a MultiRacial/Ethnic Population of Women 40–55 Years of Age. Am J Epidemiol. 2000;152(5):463–473. doi: 10.1093/aje/152.5.463.Schmidt P.J., Ben Dor R., Martinez P.E., Guerrieri G.M., Harsh V.L., Thompson K. et al. Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2015;72(7):714–726. doi: 10.1001/jamapsychiatry.2015.0111.Schmidt P.J., Ben Dor R., Martinez P.E., Guerrieri G.M., Harsh V.L., Thompson K. et al. Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2015;72(7):714–726. doi: 10.1001/jamapsychiatry.2015.0111.Rubinow D.R., Johnson S.L., Schmidt P.J., Girdler S., Gaynes B. Efficacy of Estradiol in Perimenopausal Depression: So Much Promise and So Few Answers. Depress Anxiety. 2015;32(8):539–549. doi: 10.1002/da.22391.Rubinow D.R., Johnson S.L., Schmidt P.J., Girdler S., Gaynes B. Efficacy of Estradiol in Perimenopausal Depression: So Much Promise and So Few Answers. Depress Anxiety. 2015;32(8):539–549. doi: 10.1002/da.22391.Soares C.N. Depression and Menopause: An Update on Current Knowledge and Clinical Management for this Critical Window. Med Clin North Am. 2019;103(4):651–667. doi: 10.1016/j.mcna.2019.03.001.Soares C.N. Depression and Menopause: An Update on Current Knowledge and Clinical Management for this Critical Window. Med Clin North Am. 2019;103(4):651–667. doi: 10.1016/j.mcna.2019.03.001.Li R.X., Ma M., Xiao X.R., Xu Y., Chen X.Y., Li B. Perimenopausal Syndrome and Mood Disorders in Perimenopause: Prevalence, Severity, Relationships, and Risk Factors. Medicine (Baltimore). 2016;95(32):e4466. doi: 10.1097/MD.0000000000004466.Li R.X., Ma M., Xiao X.R., Xu Y., Chen X.Y., Li B. Perimenopausal Syndrome and Mood Disorders in Perimenopause: Prevalence, Severity, Relationships, and Risk Factors. Medicine (Baltimore). 2016;95(32):e4466. doi: 10.1097/MD.0000000000004466.Yang D., Haines C.J., Pan P., Zhang Q., Sun Y., Hong S. et al. Menopausal Symptoms in Mid-Life Women in Southern China. Climacteric. 2008;11(4):329–336. doi: 10.1080/13697130802239075.Yang D., Haines C.J., Pan P., Zhang Q., Sun Y., Hong S. et al. Menopausal Symptoms in Mid-Life Women in Southern China. Climacteric. 2008;11(4):329–336. doi: 10.1080/13697130802239075.Wang H.L., Booth-LaForce C., Tang S.M., Wu W.R., Chen C.H. Depressive Symptoms in Taiwanese Women during the Peri- and Post-Menopause Years: Associations with Demographic, Health, and Psychosocial Characteristics. Maturitas. 2013;75(4):355–360. doi: 10.1016/j.maturitas.2013.04.021.Wang H.L., Booth-LaForce C., Tang S.M., Wu W.R., Chen C.H. Depressive Symptoms in Taiwanese Women during the Peri- and Post-Menopause Years: Associations with Demographic, Health, and Psychosocial Characteristics. Maturitas. 2013;75(4):355–360. doi: 10.1016/j.maturitas.2013.04.021.Unsal A., Tozun M., Ayranci U. Prevalence of Depression among Postmenopausal Women and Related Characteristics. Climacteric. 2011;14(2):244–251. doi: 10.3109/13697137.2010.510912.Unsal A., Tozun M., Ayranci U. Prevalence of Depression among Postmenopausal Women and Related Characteristics. Climacteric. 2011;14(2):244–251. doi: 10.3109/13697137.2010.510912.Freeman E.W., Sammel M.D., Lin H. Temporal Associations of Hot Flashes and Depression in the Transition to Menopause. Menopause. 2009;16(4):728–734. doi: 10.1097/gme.0b013e3181967e16.Freeman E.W., Sammel M.D., Lin H. Temporal Associations of Hot Flashes and Depression in the Transition to Menopause. Menopause. 2009;16(4):728–734. doi: 10.1097/gme.0b013e3181967e16.Bromberger J.T., Kravitz H.M., Chang Y.F., Cyranowski J.M., Brown C., Matthews K.A. Major Depression during and after the Menopausal Transition: Study of Women’s Health Across the Nation (SWAN). Psychol Med. 2011;41(9):1879–1888. doi: 10.1017/S003329171100016X.Bromberger J.T., Kravitz H.M., Chang Y.F., Cyranowski J.M., Brown C., Matthews K.A. Major Depression during and after the Menopausal Transition: Study of Women’s Health Across the Nation (SWAN). Psychol Med. 2011;41(9):1879–1888. doi: 10.1017/S003329171100016X.Пизова Н.В., Пизов А.В. Панические и депрессивные расстройства в клинической практике. Поликлиника. 2020;(6):16–19. Режим доступа: http://www.poliklin.ru/imagearticle/20206/16-19.pdf.Pizova N.V., Pizov A.V. Panic and Depressive Disorders in Clinical Practice. Poliklinika = Polyclinic. 2020;(6):16–19. (In Russ.) Available at: http://www.poliklin.ru/imagearticle/20206/16-19.pdf.Bromberger J.T., Matthews K.A., Schott L.L., Brockwell S., Avis N.E., Kravitz H.M. et al. Depressive Symptoms during the Menopausal Transition: the Study of Women’s Health Across the Nation (SWAN). J Affect Disord. 2007;103(1– 3):267–272. doi: 10.1016/j.jad.2007.01.034.Bromberger J.T., Matthews K.A., Schott L.L., Brockwell S., Avis N.E., Kravitz H.M. et al. Depressive Symptoms during the Menopausal Transition: the Study of Women’s Health Across the Nation (SWAN). J Affect Disord. 2007;103(1–3):267–272. doi: 10.1016/j.jad.2007.01.034.Freeman E.W., Sammel M.D., Lin H., Nelson D.B. Associations of Hormones and Menopausal Status with Depressed Mood in Women with No History of Depression. Arch Gen Psychiatry. 2006;63(4):375–382. doi: 10.1001/archpsyc.63.4.375.Freeman E.W., Sammel M.D., Lin H., Nelson D.B. Associations of Hormones and Menopausal Status with Depressed Mood in Women with No History of Depression. Arch Gen Psychiatry. 2006;63(4):375–382. doi: 10.1001/archpsyc.63.4.375.Schmidt P.J., Haq N., Rubinow D.R. A Longitudinal Evaluation of the Relationship between Reproductive Status and Mood in Perimenopausal Women. Am J Psychiatry. 2004;161(12):2238–2244. doi: 10.1176/appi.ajp.161.12.2238.Schmidt P.J., Haq N., Rubinow D.R. A Longitudinal Evaluation of the Relationship between Reproductive Status and Mood in Perimenopausal Women. Am J Psychiatry. 2004;161(12):2238–2244. doi: 10.1176/appi.ajp.161.12.2238.Soares C.N. Mood Disorders in Midlife Women: Understanding the Critical Window and Its Clinical Implications. Menopause. 2014;21(2):198–206. doi: 10.1097/GME.0000000000000193.Soares C.N. Mood Disorders in Midlife Women: Understanding the Critical Window and Its Clinical Implications. Menopause. 2014;21(2):198–206. doi: 10.1097/GME.0000000000000193.Worsley R., Bell R., Kulkarni J., Davis S.R. The Association between Vasomotor Symptoms and Depression during Perimenopause: A Systematic Review. Maturitas. 2014;77(2):111–117. doi: 10.1016/j.maturitas.2013.11.007.Worsley R., Bell R., Kulkarni J., Davis S.R. The Association between Vasomotor Symptoms and Depression during Perimenopause: A Systematic Review. Maturitas. 2014;77(2):111–117. doi: 10.1016/j.maturitas.2013.11.007.Natari R.B., Clavarino A.M., McGuire T.M., Dingle K.D., Hollingworth S.A. The Bidirectional Relationship between Vasomotor Symptoms and Depression across the Menopausal Transition: A Systematic Review of Longitudinal Studies. Menopause. 2018;25(1):109–120. doi: 10.1097/GME.0000000000000949.Natari R.B., Clavarino A.M., McGuire T.M., Dingle K.D., Hollingworth S.A. The Bidirectional Relationship between Vasomotor Symptoms and Depression across the Menopausal Transition: A Systematic Review of Longitudinal Studies. Menopause. 2018;25(1):109–120. doi: 10.1097/GME.0000000000000949.De Kruif M., Spijker A.T., Molendijk M.L. Depression during the Perimenopause: A Meta-Analysis. J Affect Disord. 2016;206:174–180. doi: 10.1016/j.jad.2016.07.040.De Kruif M., Spijker A.T., Molendijk M.L. Depression during the Perimenopause: A Meta-Analysis. J Affect Disord. 2016;206:174–180. doi: 10.1016/j.jad.2016.07.040.Reed S.D., Ludman E.J., Newton K.M., Grothaus L.C., LaCroix A.Z., Nekhlyudov L. et al. Depressive Symptoms and Menopausal Burden in the Midlife. Maturitas. 2009;62(3):306–310. doi: 10.1016/j.maturitas.2009.01.002.Reed S.D., Ludman E.J., Newton K.M., Grothaus L.C., LaCroix A.Z., Nekhlyudov L. et al. Depressive Symptoms and Menopausal Burden in the Midlife. Maturitas. 2009;62(3):306–310. doi: 10.1016/j.maturitas.2009.01.002.Vivian-Taylor J., Hickey M. Menopause and Depression: Is There a Link? Maturitas. 2014;79(2):142–146. doi: 10.1016/j.maturitas.2014.05.014.Vivian-Taylor J., Hickey M. Menopause and Depression: Is There a Link? Maturitas. 2014;79(2):142–146. doi: 10.1016/j.maturitas.2014.05.014.Santoro N., Epperson C.N., Mathews S.B. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015;44(3):497–515. doi: 10.1016/j.ecl.2015.05.001.Santoro N., Epperson C.N., Mathews S.B. Menopausal Symptoms and Their Management. Endocrinol Metab Clin North Am. 2015;44(3):497–515. doi: 10.1016/j.ecl.2015.05.001.Darwish M., Atlantis E., Mohamed-Taysir T. Psychological Outcomes after Hysterectomy for Benign Conditions: A Systematic Review and MetaAnalysis. Eur J Obstet Gynecol Reprod Biol. 2014;174:5–19. doi: 10.1016/j.ejogrb.2013.12.017.Darwish M., Atlantis E., Mohamed-Taysir T. Psychological Outcomes after Hysterectomy for Benign Conditions: A Systematic Review and MetaAnalysis. Eur J Obstet Gynecol Reprod Biol. 2014;174:5–19. doi: 10.1016/j.ejogrb.2013.12.017.Gibson C.J., Joffe H., Bromberger J.T., Thurston R.C., Lewis T.T., Khalil N., Matthews KA. Mood Symptoms after Natural Menopause and Hysterectomy with and without Bilateral Oophorectomy among Women in Midlife. Obstet Gynecol. 2012;119(5):935–941. doi: 10.1097/AOG.0b013e31824f9c14.Gibson C.J., Joffe H., Bromberger J.T., Thurston R.C., Lewis T.T., Khalil N., Matthews KA. Mood Symptoms after Natural Menopause and Hysterectomy with and without Bilateral Oophorectomy among Women in Midlife. Obstet Gynecol. 2012;119(5):935–941. doi: 10.1097/AOG.0b013e31824f9c14.Rocca W.A., Grossardt B.R., Geda Y.E., Gostout B.S., Bower J.H., Maraganore D.M. et al. Long-Term Risk of Depressive and Anxiety Symptoms after Early Bilateral Oophorectomy. Menopause. 2018;25(11):1275–1285. doi: 10.1097/GME.0000000000001229.Rocca W.A., Grossardt B.R., Geda Y.E., Gostout B.S., Bower J.H., Maraganore D.M. et al. Long-Term Risk of Depressive and Anxiety Symptoms after Early Bilateral Oophorectomy. Menopause. 2018;25(11):1275–1285. doi: 10.1097/GME.0000000000001229.Chou P.H., Lin C.H., Cheng C., Chang C.L., Tsai C.J., Tsai C.P. et al. Risk of Depressive Disorders in Women Undergoing Hysterectomy: A Population-Based Follow-Up Study. J Psychiatr Res. 2015;68:186–191. doi: 10.1016/j.jpsychires.2015.06.017.Chou P.H., Lin C.H., Cheng C., Chang C.L., Tsai C.J., Tsai C.P. et al. Risk of Depressive Disorders in Women Undergoing Hysterectomy: A Population-Based Follow-Up Study. J Psychiatr Res. 2015;68:186–191. doi: 10.1016/j.jpsychires.2015.06.017.Wilson L., Pandeya N., Byles J., Mishra G. Hysterectomy and Incidence of Depressive Symptoms in Midlife Women: the Australian Longitudinal Study on Women’s Health. Epidemiol Psychiatr Sci. 2018;27(4):381–392. doi: 10.1017/S2045796016001220.Wilson L., Pandeya N., Byles J., Mishra G. Hysterectomy and Incidence of Depressive Symptoms in Midlife Women: the Australian Longitudinal Study on Women’s Health. Epidemiol Psychiatr Sci. 2018;27(4):381–392. doi: 10.1017/S2045796016001220.Mulhall S., Andel R., Anstey K.J. Variation in Symptoms of Depression and Anxiety in Midlife Women by Menopausal Status. Maturitas. 2018;108: 7–12. doi: 10.1016/j.maturitas.2017.11.005.Mulhall S., Andel R., Anstey K.J. Variation in Symptoms of Depression and Anxiety in Midlife Women by Menopausal Status. Maturitas. 2018;108: 7–12. doi: 10.1016/j.maturitas.2017.11.005.Terauchi M., Hiramitsu S., Akiyoshi M., Owa Y., Kato K., Obayashi S. et al. Associations among Depression, Anxiety and Somatic Symptoms in Periand Postmenopausal Women. J Obstet Gynaecol Res. 2013;39(5):1007– 1013. doi: 10.1111/j.1447-0756.2012.02064.x.Terauchi M., Hiramitsu S., Akiyoshi M., Owa Y., Kato K., Obayashi S. et al. Associations among Depression, Anxiety and Somatic Symptoms in Periand Postmenopausal Women. J Obstet Gynaecol Res. 2013;39(5): 1007–1013. doi: 10.1111/j.1447-0756.2012.02064.x.Воробьева О.В., Русая В.В. Тревожные расстройства в неврологической практике. Лечащий врач. 2017;(5):12. Режим доступа: https://www.lvrach.ru/2017/05/15436718.Vorobieva O.V., Rusaya V.V. Anxiety Disorders in Neurological Practice. Lechaschiу Vrach. 2017;(5):12. (In Russ.) Available at: https://www.lvrach.ru/2017/05/15436718.Whiteley J., DiBonaventura M.d., Wagner J.S., Alvir J., Shah S. The Impact of Menopausal Symptoms on Quality of Life, Productivity, and Economic Outcomes. J Womens Health (Larchmt). 2013;22(11):983–990. doi: 10.1089/jwh.2012.3719.Whiteley J., DiBonaventura M.d., Wagner J.S., Alvir J., Shah S. The Impact of Menopausal Symptoms on Quality of Life, Productivity, and Economic Outcomes. J Womens Health (Larchmt). 2013;22(11):983–990. doi: 10.1089/jwh.2012.3719.Uguz F., Sahingoz M., Gezginc K., Ayhan M.G. Quality of Life in Postmenopausal Women: the Impact of Depressive and Anxiety Disorders. Int J Psychiatry Med. 2011;41(3):281–292. doi: 10.2190/PM.41.3.g.Uguz F., Sahingoz M., Gezginc K., Ayhan M.G. Quality of Life in Postmenopausal Women: the Impact of Depressive and Anxiety Disorders. Int J Psychiatry Med. 2011;41(3):281–292. doi: 10.2190/PM.41.3.g.Sowislo J.F., Orth U. Does Low Self-Esteem Predict Depression and Anxiety? A Meta-Analysis of Longitudinal Studies. Psychol Bull. 2013;139(1):213–240. doi: 10.1037/a0028931.Sowislo J.F., Orth U. Does Low Self-Esteem Predict Depression and Anxiety? A Meta-Analysis of Longitudinal Studies. Psychol Bull. 2013;139(1):213–240. doi: 10.1037/a0028931.Woods N.F., Mitchell E.S., Adams C. Memory Functioning among Midlife Women: Observations from the Seattle Midlife Women’s Health Study. Menopause. 2000;7(4):257–265. Available at: https://journals.lww.com/menopausejournal/Abstract/2000/07040/Memory_Functioning_Among_Midlife_Women_.8.aspx.Woods N.F., Mitchell E.S., Adams C. Memory Functioning among Midlife Women: Observations from the Seattle Midlife Women’s Health Study. Menopause. 2000;7(4):257–265. Available at: https://journals.lww.com/menopausejournal/Abstract/2000/07040/Memory_Functioning_Among_Midlife_Women_.8.aspx.Greendale G.A., Huang M.H., Wight R.G., Seeman T., Luetters C., Avis N.E. et al. Effects of the Menopause Transition and Hormone Use on Cognitive Performance in Midlife Women. Neurology. 2009;72(21):1850–1857. doi: 10.1212/WNL.0b013e3181a71193.Greendale G.A., Huang M.H., Wight R.G., Seeman T., Luetters C., Avis N.E. et al. Effects of the Menopause Transition and Hormone Use on Cognitive Performance in Midlife Women. Neurology. 2009;72(21):1850–1857. doi: 10.1212/WNL.0b013e3181a71193.Zhang L., Ruan X., Cui Y., Gu M., Mueck A.O. Menopausal Symptoms and Associated Social and Environmental Factors in Midlife Chinese Women. Clin Interv Aging. 2020;15:2195–2208. doi: 10.2147/CIA.S278976.Zhang L., Ruan X., Cui Y., Gu M., Mueck A.O. Menopausal Symptoms and Associated Social and Environmental Factors in Midlife Chinese Women. Clin Interv Aging. 2020;15:2195–2208. doi: 10.2147/CIA.S278976.Ахапкин Р.В., Букреева Н.Д., Вазагаева Т.И., Костюкова Е.Г., Мазо Г.Э., Мосолов С.Н. Депрессивный эпизод, рекуррентное депрессивное расстройство (взрослые): клинические рекомендации. М.; 2016. Режим доступа: https://medi.ru/klinicheskie-rekomendatsii/depressivnyj-epizodrekurrentnoe-depressivnoe-rasstrojstvo-vzroslye_13916/.Akhapkin R.V., Bukreeva N.D., Vazagaeva T.I., Kostyukova E.G., Mazo G.Eh., Mosolov S.N. Depressive episode, recurrent depressive disorder (adults): clinical guidelines. Moscow; 2016. (In Russ.) Available at: https://medi.ru/klinicheskierekomendatsii/depressivnyj-epizod-rekurrentnoe-depressivnoe-rasstrojstvovzroslye_13916/Bandelow B., Lichte T., Rudolf S., Wiltink J., Beutel M.E. The Diagnosis of and Treatment Recommendations for Anxiety Disorders. Dtsch Arztebl Int. 2014;111(27–28):473–480. doi: 10.3238/arztebl.2014.0473.Bandelow B., Lichte T., Rudolf S., Wiltink J., Beutel M.E. The Diagnosis of and Treatment Recommendations for Anxiety Disorders. Dtsch Arztebl Int. 2014;111(27–28):473–480. doi: 10.3238/arztebl.2014.0473.Zweifel J.E., O’Brien W.H. A Meta-Analysis of the Effect of hormone Replacement Therapy upon Depressed Mood. Psychoneuroendocrinology. 1997;22(3):189–212. doi: 10.1016/s0306-4530(96)00034-0.Zweifel J.E., O’Brien W.H. A Meta-Analysis of the Effect of hormone Replacement Therapy upon Depressed Mood. Psychoneuroendocrinology. 1997;22(3):189–212. doi: 10.1016/s0306-4530(96)00034-0.Ghazanfarpour M., Kaviani M., Abdolahian S., Bonakchi H., Najmabadi Khadijeh M., Naghavi M., Khadivzadeh T. The Relationship between Women’s Attitude towards Menopause and Menopausal Symptoms among Postmenopausal Women. Gynecol Endocrinol. 2015;31(11):860–865. doi: 10.3109/09513590.2015.1056138.Ghazanfarpour M., Kaviani M., Abdolahian S., Bonakchi H., Najmabadi Khadijeh M., Naghavi M., Khadivzadeh T. The Relationship between Women’s Attitude towards Menopause and Menopausal Symptoms among Postmenopausal Women. Gynecol Endocrinol. 2015;31(11):860–865. doi: 10.3109/09513590.2015.1056138.Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L. et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321–333. doi: 10.1001/jama.288.3.321.Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L. et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women’s Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321–333. doi: 10.1001/jama.288.3.321.Bond A., Lader M. A Comparison of the Psychotropic Profiles of Tofisopam and Diazepam. Eur J Clin Pharmacol. 1982;22(2):137–142. doi: 10.1007/BF00542458.Bond A., Lader M. A Comparison of the Psychotropic Profiles of Tofisopam and Diazepam. Eur J Clin Pharmacol. 1982;22(2):137–142. doi: 10.1007/BF00542458.Bernard P., Dufresne-Favetta C., Favetta P., Do Q.T., Himbert F., Zubrzycki S. et al. Application of Drug Repositioning Strategy to TOFISOPAM. Curr Med Chem. 2008;15(30):3196–3203. doi: 10.2174/092986708786848488.Bernard P., Dufresne-Favetta C., Favetta P., Do Q.T., Himbert F., Zubrzycki S. et al. Application of Drug Repositioning Strategy to TOFISOPAM. Curr Med Chem. 2008;15(30):3196–3203. doi: 10.2174/092986708786848488.Petócz L. Pharmacologic Effects of Tofizopam (Grandaxin). Acta Pharm Hung. 1993;63(2):79–82. Available at: https://pubmed.ncbi.nlm.nih.gov/8100112/.Petócz L. Pharmacologic Effects of Tofizopam (Grandaxin). Acta Pharm Hung. 1993;63(2):79–82. Available at: https://pubmed.ncbi.nlm.nih.gov/8100112/.Srivastava S., Bhatia M.S., Gupta K., Rajdev K. Current Update on Evidence Based Literature of Tofisopam. Delhi Psychiatry J. 2014;17(1):154–159. Available at: https://www.researchgate.net/profile/Kartikeya-Rajdev/publication/323746367_Current_Update_on_Evidence_Based_Literature_of_Tofisopam/links/5aa9a9b9aca272d39cd5df79/Current-Update-onEvidence-Based-Literature-of-Tofisopam.pdf.Srivastava S., Bhatia M.S., Gupta K., Rajdev K. Current Update on Evidence Based Literature of Tofisopam. Delhi Psychiatry J. 2014;17(1):154–159. Available at: https://www.researchgate.net/profile/Kartikeya-Rajdev/publication/323746367_Current_Update_on_Evidence_Based_Literature_of_Tofisopam/links/5aa9a9b9aca272d39cd5df79/Current-Update-onEvidence-Based-Literature-of-Tofisopam.pdf.Pellow S., File S.E. Is Tofisopam an Atypical Anxiolytic? Neurosci Biobehav Rev. 1986;10(2):221–227. doi: 10.1016/0149-7634(86)90026-6.Pellow S., File S.E. Is Tofisopam an Atypical Anxiolytic? Neurosci Biobehav Rev. 1986;10(2):221–227. doi: 10.1016/0149-7634(86)90026-6.Szegó J., Somogyi M., Papp E. Excerpts from the Clinical-Pharmacologic and Clinical Studies of Grandaxin. Acta Pharm Hung. 1993;63(2):91–98. Available at: https://pubmed.ncbi.nlm.nih.gov/8100114/.Szegó J., Somogyi M., Papp E. Excerpts from the Clinical-Pharmacologic and Clinical Studies of Grandaxin. Acta Pharm Hung. 1993;63(2):91–98. Available at: https://pubmed.ncbi.nlm.nih.gov/8100114/.Vakhrushev Ia.M., Belova E.V., Efremova LI. Use of Grandaxine in the Treatment of Patients with Erosive-Ulcerative Stomach and Gastroduodenal Lesions. Eksp Klin Gastroenterol. 2004;(4):21–24. Available at: https://pubmed.ncbi.nlm.nih.gov/15568662/.Vakhrushev Ia.M., Belova E.V., Efremova LI. Use of Grandaxine in the Treatment of Patients with Erosive-Ulcerative Stomach and Gastroduodenal Lesions. Eksp Klin Gastroenterol. 2004;(4):21–24. Available at: https://pubmed.ncbi.nlm.nih.gov/15568662/.Plotnikova E.Iu., Beloborodova E.I. Use of Grandaxin in Hypermotor Dysfunction of the Biliary Ducts in Young People. Eksp Klin Gastroenterol. 2005;(6):65–70, 113–114. Available at: https://pubmed.ncbi.nlm.nih.gov/17378391/.Plotnikova E.Iu., Beloborodova E.I. Use of Grandaxin in Hypermotor Dysfunction of the Biliary Ducts in Young People. Eksp Klin Gastroenterol. 2005;(6):65–70, 113–114. Available at: https://pubmed.ncbi.nlm.nih.gov/17378391/.Leventer S.M., Raudibaugh K., Frissora C.L., Kassem N., Keogh J.C., Phillips J., Mangel A.W. Clinical Trial: Dextofisopam in the Treatment of Patients with Diarrhoea-Predominant or Alternating Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2008;27(2):197–206. doi: 10.1111/j.1365-2036.2007.03566.x.Leventer S.M., Raudibaugh K., Frissora C.L., Kassem N., Keogh J.C., Phillips J., Mangel A.W. Clinical Trial: Dextofisopam in the Treatment of Patients with Diarrhoea-Predominant or Alternating Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2008;27(2):197–206. doi: 10.1111/j.1365-2036.2007.03566.x.Manabe N., Rao A.S., Wong B.S., Camilleri M. Emerging Pharmacologic Therapies for Irritable Bowel Syndrome. Curr Gastroenterol Rep. 2010;12(5):408–416. doi: 10.1007/s11894-010-0124-1.Manabe N., Rao A.S., Wong B.S., Camilleri M. Emerging Pharmacologic Therapies for Irritable Bowel Syndrome. Curr Gastroenterol Rep. 2010;12(5):408–416. doi: 10.1007/s11894-010-0124-1.Klebovich I., Abermann M. Pharmacokinetics and Metabolism of Tofizopam (Grandaxin). Acta Pharm Hung. 1993;63(2):83–90. Available at: https://pubmed.ncbi.nlm.nih.gov/8100113/.Klebovich I., Abermann M. Pharmacokinetics and Metabolism of Tofizopam (Grandaxin). Acta Pharm Hung. 1993;63(2):83–90. Available at: https://pubmed.ncbi.nlm.nih.gov/8100113/.Маркин С.П., Маркина В.А., Артемов А.Н., Чуприна С.Е., Натарова Э.Б., Есин А.А. Применение транквилизатора грандаксина при лечении психовегетативного синдрома. Прикладные информационные аспекты медицины. 2008;11(1):84–86. Режим доступа: https://new.vestnik-surgery.com/index.php/2070-9277/article/download/5319/5317.Markin S.P., Markina V.A., Artemov A.N., Chuprina S.E., Natarova E.B., Esin A.A. The Use of the Tranquilizer Grandaxin in the Treatment of Psychovegetative Syndrome. Prikladnye informatsionnye aspekty meditsiny = Applied Information Aspects of Medicine. 2008;11(1):84–86. (In Russ.) Available at: https://new.vestnik-surgery.com/index.php/2070-9277/article/download/5319/5317.Евтушенко И.Д., Зинкевич Я.С., Куценко И.Г., Белокрылова М.Ф. Эффективность применения грандаксина у пациенток с нервно-психической формой предменструального синдрома. Проблемы репродукции. 2004;10(6):76–81. Режим доступа: https://www.elibrary.ru/item.asp?id=29934747.Evtushenko I.D., Zinkevich Ya.S., Kutsenko I.G., Belokrylova M. F. Efficiency of Using Grandaxin in Patients with Neuropsychic form of Premenstrual Syndrome. Problemy reproduktsii = Reproduction Problems. 2004;10(6):76–81. (In Russ.) Available at: https://www.elibrary.ru/item.asp?id=29934747.Соловьева А.Д., Буячинская А.И. Грандаксин в лечении предменструального синдрома. Лечение нервных болезней. 2001;3 (5–2):29–31. Режим доступа: https://medi.ru/info/1664/.Solovieva A.D., Buyachinskaya A.I. Grandaxin in the Treatment of Premenstrual Syndrome. Lecheniye nervnykh bolezney = Treatment of Nervous Diseases. 2001;3(5–2):29–31. (In Russ.) Available at: https://medi.ru/info/1664/.Соколова Т.М., Яговкина Н.В. Коррекция вегетативных и психоэмоциональных нарушений при климактерическом синдроме. Проблемы репродукции. 2014;(6):92–94. doi: 10.17116/repro201420692-94.Sokolova Т.М., Yagovkina N.V. Correction of the Vegetative, Psychological and Emotional Symptoms of Climacteric Synrome. Problemy reproduktsii = Reproduction Problems. 2014;(6):92–94. (In Russ.) doi: 10.17116/repro201420692-94.Грибачева И. А., Жукова Н. Г. Вегетокорригирующее и анксиолитическое действие тофизопама в предклимактерическом периоде. Врач. 2010;(5):52–57. Режим доступа: https://medi.ru/info/2089/.Gribacheva I.A., Zhukova N.G. Vegeto-Correcting and Anxiolytic Action of Tofisopam in the Premenopausal Period. Vrach = The Doctor. 2010;(5):52–57. (In Russ.) Available at: https://medi.ru/info/2089/.Пасечников В. Д., Глухова Т. В., Уманская И. Ю., Септа И. Г. Коррекция психосоматических расстройств в комплексной терапии артериальной гипертонии у женщин в перименопаузальном периоде. Южно-российский медицинский журнал. 2002;(3):26–32. Режим доступа: https://medi.ru/info/4435/.Pasechnikov V.D., Glukhova T.V., Umanskaya I.Yu., Septa I.G. Correction of Psychosomatic Disorders in the Complex Therapy of Arterial Hypertension in Women in the Perimenopausal Period. Yuzhno-Rossiyskiy meditsinskiy zhurnal = South-Russian Medical Journal. 2002;(3):26–32. (In Russ.) Available at: https://medi.ru/info/4435/.Доброхотова Ю.Э., Сапрыкина Л.В. Тофизопам: возможность негормональной терапии нейровегетативных и психоэмоциональных нарушений при климактерическом синдроме. Медицинский совет. 2017;(2):88–91. doi: 10.21518/2079-701X-2017-2-88-91.Dobrokhotova Y.E., Saprykina L.V. Tofisopam: Prospects for Non-Hormonal Therapy of Neuro-Vegetative and Psycho-Emotional Disorders Associated with Menopausal Syndrome. Meditsinskiy sovet = Medical Council. 2017;(2):88–91. (In Russ.) doi: 10.21518/2079-701X-2017-2-88-91.Freeman E.W., Guthrie K.A., Caan B., Sternfeld B., Cohen L.S., Joffe H. et al. Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial. JAMA. 2011;305(3):267–274. doi: 10.1001/jama.2010.2016.Freeman E.W., Guthrie K.A., Caan B., Sternfeld B., Cohen L.S., Joffe H. et al. Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women: A Randomized Controlled Trial. JAMA. 2011;305(3):267–274. doi: 10.1001/jama.2010.2016.Loprinzi C.L., Sloan J.A., Perez E.A., Quella S.K., Stella P.J., Mailliard J.A. et al. Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes. J Clin Oncol. 2002;20(6):1578–1583. doi: 10.1200/JCO.2002.20.6.1578.Loprinzi C.L., Sloan J.A., Perez E.A., Quella S.K., Stella P.J., Mailliard J.A. et al. Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes. J Clin Oncol. 2002;20(6):1578–1583. doi: 10.1200/JCO.2002.20.6.1578.Joffe H., Guthrie K.A., LaCroix A.Z., Reed S.D., Ensrud K.E., Manson J.E. et al. Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms: A Randomized Clinical Trial. JAMA Intern Med. 2014 Jul;174(7):1058–1066. doi: 10.1001/jamainternmed.2014.1891.Joffe H., Guthrie K.A., LaCroix A.Z., Reed S.D., Ensrud K.E., Manson J.E. et al. Low-Dose Estradiol and the Serotonin-Norepinephrine Reuptake Inhibitor Venlafaxine for Vasomotor Symptoms: A Randomized Clinical Trial. JAMA Intern Med. 2014 Jul;174(7):1058–1066. doi: 10.1001/jamainternmed.2014.1891.Guthrie K.A., LaCroix A.Z., Ensrud K.E., Joffe H., Newton K.M., Reed S.D. et al. Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. Obstet Gynecol. 2015;126(2): 413–422. doi: 10.1097/AOG.0000000000000927.Guthrie K.A., LaCroix A.Z., Ensrud K.E., Joffe H., Newton K.M., Reed S.D. et al. Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. Obstet Gynecol. 2015;126(2):413– 422. doi: 10.1097/AOG.0000000000000927.Orleans R.J., Li L., Kim M.J., Guo J., Sobhan M., Soule L., Joffe H.V. FDA Approval of Paroxetine for Menopausal Hot Flushes. N Engl J Med. 2014;370(19):1777–1779. doi: 10.1056/NEJMp1402080.Orleans R.J., Li L., Kim M.J., Guo J., Sobhan M., Soule L., Joffe H.V. FDA Approval of Paroxetine for Menopausal Hot Flushes. N Engl J Med. 2014;370(19):1777–1779. doi: 10.1056/NEJMp1402080.Pinkerton J.V., Kagan R., Portman D., Sathyanarayana R., Sweeney M. Phase 3 Randomized Controlled Study of Gastroretentive Gabapentin for the Treatment of Moderate-to-Severe Hot Flashes in Menopause. Menopause. 2014;21(6):567–573. doi: 10.1097/GME.0b013e3182a7c073.Pinkerton J.V., Kagan R., Portman D., Sathyanarayana R., Sweeney M. Phase 3 Randomized Controlled Study of Gastroretentive Gabapentin for the Treatment of Moderate-to-Severe Hot Flashes in Menopause. Menopause. 2014;21(6):567–573. doi: 10.1097/GME.0b013e3182a7c073.Hayes L.P., Carroll D.G., Kelley K.W. Use of Gabapentin for the Management of Natural or Surgical Menopausal Hot Flashes. Ann Pharmacother. 2011;45(3):388–394. doi: 10.1345/aph.1P366.Hayes L.P., Carroll D.G., Kelley K.W. Use of Gabapentin for the Management of Natural or Surgical Menopausal Hot Flashes. Ann Pharmacother. 2011;45(3):388–394. doi: 10.1345/aph.1P366.Lavigne J.E., Heckler C., Mathews J.L., Palesh O., Kirshner J.J., Lord R. et al. A Randomized, Controlled, Double-Blinded Clinical Trial of Gabapentin 300 versus 900 mg versus Placebo for Anxiety Symptoms in Breast Cancer Survivors. Breast Cancer Res Treat. 2012;136(2):479–486. doi: 10.1007/s10549-012-2251-x.Lavigne J.E., Heckler C., Mathews J.L., Palesh O., Kirshner J.J., Lord R. et al. A Randomized, Controlled, Double-Blinded Clinical Trial of Gabapentin 300 versus 900 mg versus Placebo for Anxiety Symptoms in Breast Cancer Survivors. Breast Cancer Res Treat. 2012;136(2):479–486. doi: 10.1007/s10549-012-2251-x.Smits J.A., Berry A.C., Tart C.D., Powers M.B. The Efficacy of CognitiveBehavioral Interventions for Reducing Anxiety Sensitivity: A Meta-Analytic Review. Behav Res Ther. 2008;46(9):1047–1054. doi: 10.1016/j.brat.2008.06.010.Smits J.A., Berry A.C., Tart C.D., Powers M.B. The Efficacy of CognitiveBehavioral Interventions for Reducing Anxiety Sensitivity: A Meta-Analytic Review. Behav Res Ther. 2008;46(9):1047–1054. doi: 10.1016/j.brat.2008.06.010.Herring M.P., Lindheimer J.B., O’Connor P.J. The Effects of Exercise Training on Anxiety. Am J Lifestyle Med. 2013;8(6):388–403. doi: 10.1177/1559827613508542.Herring M.P., Lindheimer J.B., O’Connor P.J. The Effects of Exercise Training on Anxiety. Am J Lifestyle Med. 2013;8(6):388–403. doi: 10.1177/1559827613508542.Smits J.A., Berry A.C., Rosenfield D., Powers M.B., Behar E., Otto M.W. Reducing Anxiety Sensitivity with Exercise. Depress Anxiety. 2008;25(8):689–699. doi: 10.1002/da.20411.Smits J.A., Berry A.C., Rosenfield D., Powers M.B., Behar E., Otto M.W. Reducing Anxiety Sensitivity with Exercise. Depress Anxiety. 2008;25(8): 689–699. doi: 10.1002/da.20411.

The authors declare that there are no conflicts of interest present.